Sucampo Pharmaceuticals (NASDAQ:SCMP) Research Coverage Started at

assumed coverage on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a report published on Wednesday, November 15th. The brokerage issued a buy rating and a $14.00 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on SCMP. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 2nd. TheStreet downgraded Sucampo Pharmaceuticals from a c+ rating to a d rating in a research note on Wednesday, August 2nd. Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 3rd. BidaskClub downgraded Sucampo Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, August 5th. Finally, Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They set an outperform rating and a $15.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of Buy and a consensus price target of $16.00.

Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $12.80 on Wednesday. The company has a market capitalization of $596.94, a price-to-earnings ratio of 8.77, a PEG ratio of 3.81 and a beta of 1.46. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $17.24.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same period in the previous year, the business earned $0.30 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. research analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other news, insider Jason Patrick Meyenburg purchased 4,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now owns 30,228 shares in the company, valued at $366,665.64. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Louisiana State Employees Retirement System lifted its holdings in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the period. First Citizens Bank & Trust Co. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at about $116,000. JPMorgan Chase & Co. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at about $117,000. Pinnacle Associates Ltd. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at about $122,000. Finally, Trexquant Investment LP acquired a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at about $122,000. 65.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals (NASDAQ:SCMP) Research Coverage Started at” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2017/12/04/begins-coverage-on-sucampo-pharmaceuticals-inc-scmp.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply